Rei Kudo
@reikudo.bsky.social
National Cancer Center Research Institute Japan
Reposted by Rei Kudo
Fabulous plenary from Dr. Pedram Razavi #sabcs2024 on robust and innovative ai models to separate cdk4/6i responders from non-responders.
December 13, 2024 at 5:22 PM
Fabulous plenary from Dr. Pedram Razavi #sabcs2024 on robust and innovative ai models to separate cdk4/6i responders from non-responders.
Reposted by Rei Kudo
Fantastic ER+ #bcsm summary and algorithm by Dr. Danso at year in review.
First line CDK
2nd line profile driven
ADC/chemo once endo-R!
@sabcs.bsky.social
#SABCS24
@oncoalert.bsky.social
First line CDK
2nd line profile driven
ADC/chemo once endo-R!
@sabcs.bsky.social
#SABCS24
@oncoalert.bsky.social
December 13, 2024 at 11:06 PM
Fantastic ER+ #bcsm summary and algorithm by Dr. Danso at year in review.
First line CDK
2nd line profile driven
ADC/chemo once endo-R!
@sabcs.bsky.social
#SABCS24
@oncoalert.bsky.social
First line CDK
2nd line profile driven
ADC/chemo once endo-R!
@sabcs.bsky.social
#SABCS24
@oncoalert.bsky.social
Reposted by Rei Kudo
Congratulations to @reikudo.bsky.social for the beautiful work inspiring current+future studies! #SABCS24
December 14, 2024 at 3:58 AM
Congratulations to @reikudo.bsky.social for the beautiful work inspiring current+future studies! #SABCS24
Reposted by Rei Kudo
So honored to have gotten the opportunity to present our work showing a prevalent role of APOBEC3 mutagenesis in driving therapy resistance in breast cancer at #SABCS24!
December 13, 2024 at 1:11 AM
So honored to have gotten the opportunity to present our work showing a prevalent role of APOBEC3 mutagenesis in driving therapy resistance in breast cancer at #SABCS24!
Reposted by Rei Kudo
I still remember when @saratchandarlapaty.bsky.social & team discover ESR1 mutations in breast cancer by painstakingly analyzing patient samples and building lab models. Over a decade later, SERDs like imlunestrant show clear survival benefits in this population.
Follow the science.
#sabcs24
Follow the science.
#sabcs24
The selective estrogen-receptor degrader imlunestrant plus abemaciclib led to a median progression-free survival of 9.4 months among patients with ER-positive, HER2-negative breast cancer (vs. 5.5 months with imlunestrant alone). Full EMBER-3 trial results: nej.md/4fZ74HX
#MedSky #SABCS24
#MedSky #SABCS24
December 12, 2024 at 4:03 AM
I still remember when @saratchandarlapaty.bsky.social & team discover ESR1 mutations in breast cancer by painstakingly analyzing patient samples and building lab models. Over a decade later, SERDs like imlunestrant show clear survival benefits in this population.
Follow the science.
#sabcs24
Follow the science.
#sabcs24
Reposted by Rei Kudo
Congratulations to @caiy0219.bsky.social for an excellent poster presentation today! 👏🏽
Also, so happy to be reunited with @reikudo.bsky.social to represent the translational team in @saratchandarlapaty.bsky.social’s lab at #SABCS2024!
Also, so happy to be reunited with @reikudo.bsky.social to represent the translational team in @saratchandarlapaty.bsky.social’s lab at #SABCS2024!
December 12, 2024 at 3:47 AM
Congratulations to @caiy0219.bsky.social for an excellent poster presentation today! 👏🏽
Also, so happy to be reunited with @reikudo.bsky.social to represent the translational team in @saratchandarlapaty.bsky.social’s lab at #SABCS2024!
Also, so happy to be reunited with @reikudo.bsky.social to represent the translational team in @saratchandarlapaty.bsky.social’s lab at #SABCS2024!
Reposted by Rei Kudo
OncoAlert & @sabcs.bsky.social 🚨Announce Special Collaboration to Deliver Top #SABCS24 #BreastCancer News
Covering all Platforms
Linkedin: https://buff.ly/4f37sDT
X: https://buff.ly/49iPrjV
Facebook: https://buff.ly/4g5qquK
Instagram: https://buff.ly/49lquV8
Threads: https://buff.ly/3B7ZHih
Covering all Platforms
Linkedin: https://buff.ly/4f37sDT
X: https://buff.ly/49iPrjV
Facebook: https://buff.ly/4g5qquK
Instagram: https://buff.ly/49lquV8
Threads: https://buff.ly/3B7ZHih
December 2, 2024 at 3:39 PM
OncoAlert & @sabcs.bsky.social 🚨Announce Special Collaboration to Deliver Top #SABCS24 #BreastCancer News
Covering all Platforms
Linkedin: https://buff.ly/4f37sDT
X: https://buff.ly/49iPrjV
Facebook: https://buff.ly/4g5qquK
Instagram: https://buff.ly/49lquV8
Threads: https://buff.ly/3B7ZHih
Covering all Platforms
Linkedin: https://buff.ly/4f37sDT
X: https://buff.ly/49iPrjV
Facebook: https://buff.ly/4g5qquK
Instagram: https://buff.ly/49lquV8
Threads: https://buff.ly/3B7ZHih
I also LOVE rational therapeutics.
Data like this is why I believe in rational therapeutics. It’s easy to dismiss targeted therapy as doomed to resistance, but really, we are just scratching the surface of mechanisms. And understanding mechanisms will allow us to develop not just A DRUG, but ultimately A STRATEGY to defeat cancer.
NEW #Oncology:
EGFR expression mediates resistance to T-DXd (EGFR overexpression ⬇️ HER2 homodimerization & HER2/ADC internalization)
Combining with EGFR mAbs restored HER2/ADC trafficking & ⬆️ activity in nonclinical models
#DrugDevelopment #OncoSky
www.cell.com/cell-reports...
EGFR expression mediates resistance to T-DXd (EGFR overexpression ⬇️ HER2 homodimerization & HER2/ADC internalization)
Combining with EGFR mAbs restored HER2/ADC trafficking & ⬆️ activity in nonclinical models
#DrugDevelopment #OncoSky
www.cell.com/cell-reports...
November 22, 2024 at 11:02 PM
I also LOVE rational therapeutics.